Fujitsu Launches SaaS Solution for Clinical Drug Trials

and Fujitsu Limited today announced the launch of software as a service ()-based solution to support the operation of clinical drug trials conducted by pharmaceutical companies. The new service, called tsClinical, is now available in Japan.

tsClinical is an on-demand -based solution that provides a for results from medical cases necessary for clinical trials of new drugs, according to trial length and scale, through a network.

The new service eliminates the need for users to deploy an individual case for each clinical trial, thus speeding up the trial process, eliminating and maintenance costs, and minimizing the workload associated with clinical trials.

tsClinical has already been deployed by Bellsystem24, Inc., a Japan- which provides support services for clinical trials. In addition to existing support services, Bellsystem24 aims to deliver enhanced CRO(1) services by providing new services, connecting its pharmaceutical customers with a data through .

Pharmaceutical companies, , and CROs have been conducting a variety of clinical trials to test new drugs for lifestyle-related diseases, infectious diseases, and healthcare maintenance, as well as to determine the side effects of drugs already on the market. However, during these clinical trials, it is important for companies to collect and manage data containing information on the effectiveness or side effects of a drug, both quickly and accurately. Companies must also employ a case that complies with related regulations for each respective clinical trial. As a result, it has become a challenge for pharmaceutical companies to quickly deploy case data management systems to conduct fast clinical trials while curtailing system development costs.

To optimize clinical trial operations during new drug development, Fujitsu is offering an on-demand -based , which previously was only available as a software package.

Full Source

Tags: , , , , , , , , ,

No comments yet.

Leave a Reply